Peter Hulick to Prostatic Neoplasms
This is a "connection" page, showing publications Peter Hulick has written about Prostatic Neoplasms.
Connection Strength
0.662
-
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022 09; 25(3):422-430.
Score: 0.090
-
Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. Prostate. 2021 09; 81(13):1002-1008.
Score: 0.086
-
Calibration of polygenic risk scores is required prior to clinical implementation: results of three common cancers in UKB. J Med Genet. 2022 03; 59(3):243-247.
Score: 0.083
-
Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. Eur Urol. 2021 03; 79(3):419-426.
Score: 0.082
-
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
Score: 0.077
-
Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 01 25; 10(1):431.
Score: 0.072
-
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
Score: 0.063
-
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
Score: 0.058
-
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014 Sep; 66(3):489-99.
Score: 0.051